ABSTRACT
Background: This pandemic has impacted health and the economy worldwide on an unprecedented scale. It has important systemic effects including the cardiovascular and immune systems. Aim(s): Discuss the links between COVID-19 clinical features and complications and its hematological findings and coagulopathy. This link may shed light on our prognostic view to patients with COVID-19 and will have significant therapeutic implications. One of these important implications is the use of mesenchymal stem cells (MSCs) to treat COVID-19 patients. Method(s): Review done to Autopsy findings support the concept that the pathogenesis of severe COVID-19 involves direct viral-induced injury of multiple organs, including heart and lungs, coupled with the consequences of a procoagulant state with coagulopathy. Mesenchymal stem cells as a potential therapy for COVID-19 INFECTION. Result(s): Mesenchymal stem cells (MSCs) can be isolated from different adult tissues, and neonatal birth-associated tissues, including placenta (PL), umbilical cord (UC), Warton jelly (WJ), amniotic fluid (AF), and cord blood (CB), and then stored for future possible applications. Differentiation potential, powerful immunoregulation, and endogenous repair mechanisms. Support to potential use of MSCs in treating patients came from observations that MSCs have been identified to efficiently cure ALI/ARDS from both infectious and noninfectious causes, mediated primarily by paracrine mechanisms based on the released extracellular vesicles (EVs). The immune-regulation of MSCs depends mainly on modulating activation and effector function of immune cells, suppressing lung-infiltrated cells, and enhancing the resolution of pulmonary edema [35]. Conclusion(s): COVID-19 is associated with distinct hematological changes, rise in serum inflammatory markers, and coagulopathy. Most of these changes were related to the patients' prognosis and mortality, particularly in those with severe disease. There are links between COVID-19 clinical features and complications and its hematological findings and coagulopathy. COVID-19 patients seems to be a promising approach. Further studies are needed to clarify more clinic-pathologic links in COVID-19 that might improve outcomes.